| Liu, Zhanzhong |
| Recruiting | N/A | 10000 | RoW | | Eastern Hepatobiliary Surgery Hospital | Carcinoma, Hepatocellular | 07/22 | 07/23 | | |
| Peng, Le |
| Completed | 4 | 354 | RoW | PZA sensitivity guided ultra-short all Oral Regimen, Standardized Shorter Regimen | Huashan Hospital | Multidrug Resistant Tuberculosis | 08/24 | 08/24 | | |
| Li, Jing-Xin |
NCT05148949: Study on Three Doses of an Inactivated COVID-19 Vaccine in Chinese Pulmonary Tuberculosis Patients |
|
|
| Recruiting | 4 | 240 | RoW | Standard dosage inactivated vaccine, Standard dosage CoronaVac, Double dosage inactivated vaccine, Double dosage CoronaVac | Jiangsu Province Centers for Disease Control and Prevention | COVID-19, Pulmonary Tuberculosis | 12/22 | 03/23 | | |
NCT05855408: Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults |
|
|
| Not yet recruiting | 4 | 10000 | RoW | Intramuscularly administered Ad5-nCoV vaccine, Aerosolized Ad5-nCoV, DelNS1-2019-nCoV-RBD-OPT1, SYS6006 | Jiangsu Province Centers for Disease Control and Prevention | COVID-19 | 05/24 | 12/24 | | |
NCT06609811: The Interaction Between Mucosal Microbiota Colonization and the Immune Response to an Intranasal Influenza Live Attenuated Vaccine |
|
|
| Not yet recruiting | 4 | 200 | NA | Intranasal Influenza Live Attenuated Vaccine | Jiangsu Province Centers for Disease Control and Prevention | Influenza | 06/25 | 07/25 | | |
NCT05043259: Heterologous Prime-boost Immunization With an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming With an Inactivated SARS-CoV-2 Vaccine |
|
|
| Active, not recruiting | 1/2 | 420 | RoW | inactive SARS-CoV-2 vaccine (Vero cell), Low dose aerosolized Ad5-nCoV, High dose aerosolized Ad5-nCoV | Jiangsu Province Centers for Disease Control and Prevention | COVID-19 | 08/22 | 12/22 | | |
| Du, Ronghui |
NCT06305104: Clinical Trial to Explore the Skin Test Dosage of EEC in People Aged 18 to 65 Years Old and the Safety and Preliminary Efficacy in People Aged 3 to 75 Years Old. |
|
|
| Recruiting | 2 | 420 | RoW | 2.5μg/ml EEC, 5μg/ml EEC, 5 unit（U） EC | Chengdu CoenBiotech Co., Ltd, Beijing Chest Hospital, Capital Medical University, Wuhan Institute for Tuberculosis Control, The Public Health Clinical Center of Chengdu, Xuzhou Infectious Disease Hospital, Jiangsu Province Centers for Disease Control and Prevention, Changde First People's Hospital | Tuberculosis | 05/24 | 06/24 | | |
NCT06525272: A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT in Patients With Pleurisy |
|
|
| Not yet recruiting | 1 | 72 | RoW | Recombinant Human Chymotrypsin(OsrhCT), Freeze-dried Powder of Recombinant Human Chymotrypsin(OsrhCT), Placebo for Recombinant Human Chymotrypsin(OsrhCT), Freeze-dried Powder of Placebo for Recombinant Human Chymotrypsin(OsrhCT) | Healthgen Biotechnology Corp. | Pleurisy | 07/25 | 12/25 | | |
